ASX Share rice
Mon 17 May 2021 - 03:34:am (Sydney)

SUD Share Price

SUDA PHARMACEUTICALS LTDSUDPharmaceuticals, Biotechnology & Life Sciences

SUD Company Information

Name:

Suda Pharmaceuticals Ltd

Sector:

Healthcare

Industry:

Biotechnology

GIC Industry:

Pharmaceuticals

GIC Sub Industry:

Pharmaceuticals

Address:

55 Howe Street Osborne Park WA Australia 6017

Phone:

61 8 6142 5555

CEO, MD, CTO & Director:

Dr. Michael Baker

Consultant:

Mr. Stephen John Carter

Exec. Director:

Mr. David Phillips

Company Sec. & CFO:

Mr. Phillip Hains C.A., M.B.A., B Bus, CA, MBA

Project Director & Member of Scientific Advisory Board:

Dr. Richard Franklin

GM & CTO:

Tony Macintyre

Company Overview:

Suda Pharmaceuticals Ltd engages in the development of drug delivery technology in Australia, India, Europe and Korea. It offers ZolpiMist, an oro-mucosal spray formulation of zolpidem tartrate marketed under the brand name of Ambien or Stilnox, a non-benzodiazepine prescribed for the short-term treatment of insomnia. The company's product pipeline includes Sumatriptan, an oral spray formulation for the treatment of acute migraine; and anagrelide, a platelet lowering agent for use in thrombosis, which is used for the treatment of cancer. Suda Pharmaceuticals Ltd has license and supply agreement with Teva Pharmaceuticals International GmbH and Mitsubishi Tanabe Pharma Singapore for ZolpiMist oral spray; product development, licence, and supply agreement with Cann Pharmaceutical Australia Ltd for the development of novel oral spray of pharmaceutical-grade cannabinoid derivatives for the treatment of drug resistant epilepsy, melanoma, and motion sickness; and feasibility and option agreement with Zelira Therapeutics for the use of cannabinoids for a range of uses, including insomnia, autism, opioid reduction, anxiety, pain, and cancer. The company also has a feasibility study and option agreement with Laboratorios Ordesa, S.L. The company was formerly known as Suda Limited and changed its name to Suda Pharmaceuticals Ltd in November 2017. Suda Pharmaceuticals Ltd was incorporated in 1999 and is headquartered in Osborne Park, Australia.

SUD Share Price Information

Shares Issued:

384.66M

Market Capitalisation:

$13.46M

Revenue (TTM):

$563.93K

Revenue Per Share (TTM):

$0

Earnings per Share:

$-0.003

Operating Margin (TTM):

$-7.77

Return On Assets (TTM):

$-0.30

Return On Equity (TTM):

$-0.53

Quarterly Revenue Growth (YOY):

-0.082

Gross Profit(TTM):

$370.96K

Diluted Earnings Per Share (TTM):

$-0.019

SUD CashFlow Statement

CashFlow Date:

2020-06-30

Investments:

$-388,422

Change To Liabilities:

$564.51K

Total Cashflow From Investing Activities:

$-388,422

Net Borrowings:

$-63,943

Net Income:

$-9,935,595

Total Cash From Operating Activities:

$-2,883,725

Depreciation:

$222.98K

Change To Account Receivables:

$251.34K

Capital Expenditures:

$141.09K

SUD Income Statement

Income Date:

2020-06-30

Income Before Tax:

$-10,591,480

Net Income:

$-9,935,600

Gross Profit:

$375.23K

Operating Income:

$-10,633,060

Other Operating Expenses:

$3.02M

Interest Expense:

$6.57K

Income Tax Expense:

$-655,882

Total Revenue:

$576.20K

Cost Of Revenue:

$200.97K

SUD Balance Sheet

Balance Sheet Date:

2020-06-30

Intangible Assets:

$4.25M

Total Liabilities:

$2.57M

Total Stockholder Equity:

$4.14M

Other Current Liabilities:

$1.03M

Total Assets:

$6.71M

Common Stock:

$67.39M

Other Current Assets:

$166.20K

Retained Earnings:

$-64,880,540

Other Liabilities:

$545.36K

Other Assets:

$4.12M

Cash:

$0.98M

Total Current Liabilities:

$2.02M

Property - Plant & Equipment:

$421.63K

Net Tangible Assets:

$4M

Total Current Assets:

$2.03M

Long-Term Debt:

$4.24K

Net Receivables:

$0.99M

Short-Term Investments:

$4.67M

Inventory:

$21.80K

Accounts Payable:

$732.07K

Short-Term Investments:

$4.67

Non Current Liabilities Total:

$549.60K

SUD Share Price History

SUD News